{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:15:40Z","timestamp":1759335340887,"version":"3.37.3"},"reference-count":14,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100016317","name":"CAPS Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016317","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.urolonc.2024.01.019","type":"journal-article","created":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T00:56:03Z","timestamp":1706835363000},"page":"223-228","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Standardization of the evaluation and surveillance of patients with BCG unresponsive high grade non-muscle invasive bladder cancer clinical trials"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5692-2723","authenticated-orcid":false,"given":"Yair","family":"Lotan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piyush","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Black","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rian","family":"Dickstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashish M.","family":"Kamat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byron","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vikram M.","family":"Narayan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sima","family":"Porten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah P.","family":"Psutka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armine K.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert S.","family":"Svatek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen B.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Solomon","family":"Woldu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2024.01.019_bib0001","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3233\/BLC-230056","article-title":"Advancing clinical trial design for non-muscle invasive bladder cancer","volume":"9","author":"Chang","year":"2023","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.urolonc.2024.01.019_bib0002","article-title":"Bladder cancer, version 3.2023 bladder cancer NCCN guidelines","author":"Flaig","year":"2023","journal-title":"J. Natl Compr Canc Netw"},{"key":"10.1016\/j.urolonc.2024.01.019_bib0003","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multi- centre, phase 2 study","volume":"22","author":"Balar","year":"2021","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2024.01.019_bib0004","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial","volume":"22","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2024.01.019_bib0005","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1097\/JU.0000000000002308","article-title":"Utility of blue light cystoscopy for post-bacillus Calmette-Gu\u00e9rin bladder cancer recurrence detection: implications for clinical trial recruitment and study comparisons","volume":"207","author":"Chappidi","year":"2022","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.urolonc.2024.01.019_bib0006","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.purol.2023.03.003","article-title":"Photodynamic cystoscopy for bladder cancer diagnosis and for NMIBC follow-up: an overview of systematic reviews and meta-analyses","volume":"33","author":"Soorojebally","year":"2023","journal-title":"Prog Urol"},{"key":"10.1016\/j.urolonc.2024.01.019_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2024.01.019_bib0008","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.urology.2005.02.003","article-title":"Correlation of office-based cystoscopy and cytology with histologic diagnosis: how good is the reference standard?","volume":"66","author":"Svatek","year":"2005","journal-title":"Urology"},{"issue":"5","key":"10.1016\/j.urolonc.2024.01.019_bib0009","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.juro.2017.11.096","article-title":"Efficacy and safety of blue light flexible cystoscopy with hexaminolevulinate in the surveillance of bladder cancer: a phase III, Comparative, Multicenter Study","volume":"199","author":"Daneshmand","year":"2018","journal-title":"J Urol."},{"year":"2022","series-title":"WHO classification of tumours: urinary and male genital tumours","author":"Netto","key":"10.1016\/j.urolonc.2024.01.019_bib0010"},{"issue":"6","key":"10.1016\/j.urolonc.2024.01.019_bib0011","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/dc.24952","article-title":"The Paris system classification for urinary cytology in patients under bacillus Calmette-Guerin treatment","volume":"50","author":"Moulavasilis","year":"2022","journal-title":"Diagn Cytopathol"},{"key":"10.1016\/j.urolonc.2024.01.019_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2023.08.004","article-title":"Phase 2 trial of atezolizumab in bacillus Calmette-Gu\u00e9rin-unresponsive high-risk non-muscle-invasive bladder cancer: SWOG S1605","author":"Black","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2024.01.019_bib0013","unstructured":"Chamie K, Chang SS, Kramolowsky E, et al. IL-15 Superagonist NAI in BCG-Unresponsive Non\u2013Muscle-Invasive Bladder Cancer. https:\/\/evidence.nejm.org\/doi\/full\/10.1056\/EVIDoa2200167"},{"key":"10.1016\/j.urolonc.2024.01.019_bib0014","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.23.00307","article-title":"Definitions, end points, and clinical trial designs for bladder cancer: recommendations from the society for immunotherapy of cancer and the international bladder cancer group","author":"Kamat","year":"2023","journal-title":"J Clin Oncol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143924000206?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143924000206?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T09:58:06Z","timestamp":1729245486000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143924000206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":14,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S1078143924000206"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.01.019","relation":{},"ISSN":["1078-1439"],"issn-type":[{"type":"print","value":"1078-1439"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Standardization of the evaluation and surveillance of patients with BCG unresponsive high grade non-muscle invasive bladder cancer clinical trials","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.01.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}